Elizabeth A. Barrett - 28 Jul 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Executive Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
28 Jul 2025
Net transactions value
$0
Form type
4
Filing time
30 Jul 2025, 16:08:22 UTC
Previous filing
23 Jun 2025
Next filing
31 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Barrett Elizabeth A. Chief Executive Officer 400 ALEXANDER PARK DRIVE, PRINCETON /s/ Jason D. Smith, Attorney-in-Fact 30 Jul 2025 0001764157

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Performance Stock Units Award $0 +87,615 $0.000000 87,615 28 Jul 2025 Ordinary Shares 87,615 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents performance stock units ("PSUs") granted to the reporting person on January 31, 2024 that were earned upon the achievement of a corporate milestone event. These PSUs remain subject to continued service through December 31, 2025, at which time they will vest and settle in ordinary shares.